Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Baseline disease activity and PRO scores (ITT population)

From: Rapid and sustained improvements in health-related quality of life, fatigue, and other patient-reported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1 year: results from the RAPID 1 randomized controlled trial

Characteristic, mean (SD) CZP 200 mg + MTX
(n = 393)
CZP 400 mg + MTX
(n = 390)
PBO + MTX
(n = 199)
DAS28, range 0-10 6.9 (0.8) 6.9 (0.8) 7.0 (0.9)
PtGA VAS, range 0-100 mm 63.1 (20.3) 64.1 (18.3) 64.2 (19.6)
Pain VAS, range 0-100 mm 62.1 (20.0) 63.8 (17.2) 63.6 (19.9)
HAQ-DI, range 0-3 1.7 (0.6) 1.7 (0.6) 1.7 (0.6)
Fatigue NRS, range 0-10 6.4 (2.0) 6.5 (1.9) 6.7 (2.0)
SF-36    
   PCS, range 0-100* 30.9 (6.5) 30.8 (6.8) 30.5 (5.8)
   MCS, range 0-100* 40.0 (11.2) 39.3 (11.1) 38.6 (11.4)
   Domains, range 0-100    
Physical Functioning 33.4 (21.4) 32.9 (21.2) 32.0 (20.1)
Role Physical 13.3 (23.7) 12.9 (25.4) 11.2 (20.8)
Bodily Pain 30.6 (15.3) 28.9 (15.9) 28.5 (14.7)
General Health 35.3 (16.5) 35.9 (17.5) 34.9 (15.6)
Vitality 35.8 (18.0) 36.1 (18.6) 32.9 (17.4)
Social Functioning 50.9 (23.8) 48.1 (24.0) 46.6 (25.2)
Role Emotional 32.4 (39.1) 28.9 (38.1) 30.9 (38.7)
Mental Health 53.8 (20.1) 53.5 (20.7) 52.2 (21.2)
  1. * mean US population normative value equals 50
  2. CZP = certolizumab pegol; DAS28 = disease activity score; HAQ-DI = health assessment questionnaire-disability index; ITT = intent to treat; MCS = mental component summary; MTX = methotrexate; NRS = numeric rating scale; PBO = placebo; PCS = physical component summary; PRO = patient-reported outcomes; PtGA = patient's global assessment of disease activity; SD = standard deviation; SF-36 = short-form 36-item health survey; VAS = visual analog scale.